Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio [CORRESPONDENCE]
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Indini, Di Nicola, Del Vecchio, De Braud Tags: CORRESPONDENCE Source Type: research
More News: Cancer & Oncology | Yervoy